This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies | OLS miRNA effect size | OLS covariates effect size |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-107 | WIF1 | 0.35 | 0.52382 | 2.05 | 3.0E-5 | miRanda | -0.81 | 1.0E-5 | NA | -0.81 | type:-3.39, stage:-0.37, histology:-0.15, PAM50:-0.45, ER:0.11, PR:0.07, HER2:-0.17, Triple_Negative:1.68 | |
2 | hsa-miR-484 | SFRP1 | 0.41 | 0.45389 | 3.81 | 0 | MirTarget | -0.74 | 0 | NA | -0.79 | type:-5.75, stage:-0.19, histology:-0.12, PAM50:-1.1, ER:0.39, PR:-0.38, HER2:-1.15, Triple_Negative:1.64 | |
3 | hsa-miR-1301-3p | SFRP1 | 1.13 | 0.00036 | 3.81 | 0 | MirTarget | -0.63 | 0 | NA | -0.54 | type:-5.36, stage:-0.13, histology:-0.13, PAM50:-1.1, ER:0.15, PR:-0.44, HER2:-0.96, Triple_Negative:1.68 | |
4 | hsa-miR-16-5p | WNT5A | 0.61 | 0.44106 | -0.49 | 0.23864 | miRNAWalker2 validate | -0.44 | 0 | NA | -0.48 | type:2.47, stage:-0.21, histology:-0.1, PAM50:-0.03, ER:-0.02, PR:0.72, HER2:0.36, Triple_Negative:0.35 | |
5 | hsa-miR-107 | FZD10 | 0.35 | 0.52382 | -0.3 | 0.16314 | miRanda | -0.4 | 0 | NA | -0.45 | type:0.61, stage:-0.18, histology:0.07, PAM50:-0.05, ER:0.42, PR:-0.11, HER2:-0.2, Triple_Negative:0.04 | |
6 | hsa-miR-590-3p | WIF1 | 1.01 | 0 | 2.05 | 3.0E-5 | PITA; miRanda; mirMAP | -0.64 | 0 | NA | -0.44 | type:-3.84, stage:-0.32, histology:-0.14, PAM50:-0.54, ER:-0.07, PR:0.06, HER2:-0.11, Triple_Negative:1.5 | |
7 | hsa-miR-24-3p | CAMK2B | 0.83 | 0.36962 | -1.56 | 0 | MirTarget | -0.67 | 0 | NA | -0.42 | type:3.05, stage:0.05, histology:0.05, PAM50:0.45, ER:0.64, PR:0.38, HER2:-0.14, Triple_Negative:0.63 | |
8 | hsa-miR-30e-5p | WNT5A | 0.74 | 0.51197 | -0.49 | 0.23864 | mirMAP | -0.36 | 0 | NA | -0.41 | type:2.04, stage:-0.22, histology:-0.12, PAM50:-0.11, ER:0.07, PR:0.74, HER2:0.34, Triple_Negative:0.28 | |
9 | hsa-miR-17-3p | FZD4 | 1.47 | 0.04186 | -0.76 | 0.18617 | MirTarget | -0.49 | 0 | NA | -0.37 | type:-3.88, stage:-0.05, histology:-0.03, PAM50:-0.05, ER:-0.26, PR:-0.11, HER2:0.08, Triple_Negative:-0.65 | |
10 | hsa-miR-200c-3p | FZD4 | 0.37 | 0.75644 | -0.76 | 0.18617 | mirMAP | -0.54 | 0 | NA | -0.37 | type:-3.68, stage:-0.04, histology:-0.01, PAM50:0.03, ER:-0.31, PR:-0.11, HER2:0.07, Triple_Negative:-0.95 | |
11 | hsa-miR-92a-3p | WNT5A | 1.23 | 0.30313 | -0.49 | 0.23864 | miRNAWalker2 validate | -0.46 | 0 | NA | -0.37 | type:2.07, stage:-0.21, histology:-0.11, PAM50:-0.09, ER:0, PR:0.73, HER2:0.4, Triple_Negative:0.41 | |
12 | hsa-miR-30c-5p | WNT7B | 0.29 | 0.7388 | -0.96 | 0.01632 | miRNATAP | -0.46 | 0 | NA | -0.37 | type:0.5, stage:0.09, histology:-0.12, PAM50:0.23, ER:-0.16, PR:-0.38, HER2:0.51, Triple_Negative:-0.87 | |
13 | hsa-miR-96-5p | SFRP1 | 0.1 | 0.81662 | 3.81 | 0 | mirMAP | -0.84 | 0 | NA | -0.36 | type:-5.51, stage:-0.13, histology:-0.1, PAM50:-1.1, ER:0.29, PR:-0.23, HER2:-1.11, Triple_Negative:1.38 | |
14 | hsa-miR-589-5p | CXXC4 | 0.23 | 0.66837 | -1.31 | 0 | MirTarget; miRNATAP | -0.4 | 0 | NA | -0.35 | type:-0.45, stage:-0.16, histology:-0.05, PAM50:0.36, ER:0.35, PR:-0.67, HER2:0.29, Triple_Negative:-0.74 | |
15 | hsa-miR-16-1-3p | SFRP1 | 0.42 | 0.04437 | 3.81 | 0 | MirTarget | -0.71 | 0 | NA | -0.35 | type:-5.14, stage:-0.13, histology:-0.1, PAM50:-1.13, ER:0.51, PR:-0.19, HER2:-1.02, Triple_Negative:1.71 | |
16 | hsa-miR-362-5p | CAMK2B | 0.82 | 0.01076 | -1.56 | 0 | miRNATAP | -0.37 | 0 | NA | -0.34 | type:2.37, stage:0.09, histology:0.04, PAM50:0.48, ER:0.51, PR:0.38, HER2:-0.17, Triple_Negative:0.47 | |
17 | hsa-miR-330-5p | WIF1 | 0.56 | 0.19479 | 2.05 | 3.0E-5 | miRanda | -0.66 | 0 | NA | -0.34 | type:-3.56, stage:-0.36, histology:-0.14, PAM50:-0.49, ER:0.1, PR:0.15, HER2:-0.11, Triple_Negative:1.58 | |
18 | hsa-miR-141-3p | FZD4 | 0.52 | 0.54365 | -0.76 | 0.18617 | TargetScan | -0.49 | 0 | NA | -0.33 | type:-3.26, stage:-0.07, histology:-0.01, PAM50:0.04, ER:-0.28, PR:-0.14, HER2:0.08, Triple_Negative:-0.91 | |
19 | hsa-miR-7-1-3p | SFRP1 | -0.14 | 0.72688 | 3.81 | 0 | MirTarget; mirMAP | -0.63 | 0 | NA | -0.31 | type:-6.3, stage:-0.1, histology:-0.11, PAM50:-1.1, ER:0.41, PR:-0.25, HER2:-1.13, Triple_Negative:1.41 | |
20 | hsa-miR-374a-5p | WNT3 | 0.47 | 0.30955 | -0.24 | 0.21582 | MirTarget | -0.45 | 0 | NA | -0.31 | type:2.78, stage:-0.04, histology:0.03, PAM50:0.32, ER:0.64, PR:-0.13, HER2:-0.56, Triple_Negative:0.95 | |
21 | hsa-miR-98-5p | FZD10 | 0.61 | 0.24397 | -0.3 | 0.16314 | miRNAWalker2 validate | -0.46 | 0 | NA | -0.3 | type:0.29, stage:-0.15, histology:0.06, PAM50:-0.11, ER:0.43, PR:-0.08, HER2:-0.2, Triple_Negative:-0.03 | |
22 | hsa-miR-200b-3p | FZD4 | 0.22 | 0.78639 | -0.76 | 0.18617 | mirMAP | -0.44 | 0 | NA | -0.3 | type:-3.23, stage:-0.08, histology:-0.02, PAM50:0.01, ER:0.06, PR:-0.15, HER2:0.02, Triple_Negative:-0.78 | |
23 | hsa-miR-30d-5p | CAMK2A | 0.17 | 0.88286 | -0.12 | 0.63413 | mirMAP | -0.5 | 0 | NA | -0.29 | type:1.39, stage:-0.09, histology:-0.14, PAM50:-0.14, ER:0.42, PR:-0.05, HER2:0.52, Triple_Negative:0 | |
24 | hsa-miR-141-5p | DAAM2 | 0.15 | 0.85459 | -0.04 | 0.92488 | mirMAP | -0.39 | 0 | NA | -0.29 | type:-0.82, stage:0, histology:0.11, PAM50:-0.11, ER:0.4, PR:-0.19, HER2:-0.11, Triple_Negative:-0.02 | |
25 | hsa-miR-330-5p | FZD4 | 0.56 | 0.19479 | -0.76 | 0.18617 | miRanda; miRNATAP | -0.41 | 0 | NA | -0.28 | type:-3.62, stage:-0.05, histology:-0.03, PAM50:0.01, ER:-0.2, PR:-0.04, HER2:0.17, Triple_Negative:-0.78 | |
26 | hsa-miR-29c-3p | PRKX | -0.64 | 0.52285 | 1.92 | 3.0E-5 | mirMAP | -0.39 | 0 | NA | -0.28 | type:-0.81, stage:-0.07, histology:-0.09, PAM50:-0.28, ER:-0.22, PR:-0.2, HER2:-0.22, Triple_Negative:0.74 | |
27 | hsa-miR-93-5p | CCND2 | 0.94 | 0.3985 | -0.07 | 0.88928 | miRNATAP | -0.4 | 0 | NA | -0.27 | type:-1.71, stage:-0.02, histology:-0.1, PAM50:-0.08, ER:-0.12, PR:0.12, HER2:-0.02, Triple_Negative:-0.02 | |
28 | hsa-miR-660-5p | CXXC4 | 0.79 | 0.10863 | -1.31 | 0 | miRNATAP | -0.56 | 0 | NA | -0.27 | type:-0.88, stage:-0.14, histology:-0.07, PAM50:0.32, ER:0.43, PR:-0.69, HER2:0.13, Triple_Negative:-0.68 | |
29 | hsa-miR-361-5p | PRICKLE2 | 0.3 | 0.67981 | -1.2 | 0.01176 | MirTarget; PITA; miRanda; miRNATAP | -0.42 | 0 | NA | -0.27 | type:-1.45, stage:-0.06, histology:-0.03, PAM50:0.06, ER:0.28, PR:0.18, HER2:0.17, Triple_Negative:-0.61 | |
30 | hsa-miR-29b-2-5p | PRKCA | -1.15 | 0.02347 | 1.09 | 0.00099 | mirMAP | -0.37 | 0 | NA | -0.27 | type:-2.76, stage:-0.04, histology:-0.05, PAM50:-0.2, ER:-0.02, PR:-0.23, HER2:-0.2, Triple_Negative:0.06 | |
31 | hsa-miR-141-3p | SOX17 | 0.52 | 0.54365 | -0.56 | 0.03082 | TargetScan | -0.43 | 0 | 22921431 | Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer; MicroRNA 141 was also found to down-regulate SOX17 expression and activate the WNT signal pathway | -0.27 | type:-1.81, stage:-0.08, histology:0.04, PAM50:0.02, ER:0.02, PR:-0.01, HER2:-0.05, Triple_Negative:-0.32 |
32 | hsa-miR-532-5p | CXXC4 | 0.84 | 0.32413 | -1.31 | 0 | MirTarget; PITA; miRNATAP | -0.5 | 0 | NA | -0.26 | type:-0.91, stage:-0.15, histology:-0.07, PAM50:0.33, ER:0.4, PR:-0.7, HER2:0.15, Triple_Negative:-0.69 | |
33 | hsa-miR-182-5p | SFRP1 | -0.35 | 0.79413 | 3.81 | 0 | mirMAP | -0.97 | 0 | NA | -0.26 | type:-5.71, stage:-0.14, histology:-0.11, PAM50:-1.11, ER:0.42, PR:-0.17, HER2:-1.08, Triple_Negative:1.42 | |
34 | hsa-miR-2355-5p | CAMK2B | 0.52 | 0.30108 | -1.56 | 0 | mirMAP | -0.53 | 0 | NA | -0.25 | type:2.82, stage:0.06, histology:0.06, PAM50:0.48, ER:0.63, PR:0.36, HER2:-0.11, Triple_Negative:0.44 | |
35 | hsa-miR-342-3p | FOSL1 | -0.72 | 0.32809 | 2.26 | 0 | miRanda | -0.4 | 0 | NA | -0.25 | type:-0.72, stage:-0.06, histology:-0.05, PAM50:-0.31, ER:-0.41, PR:-0.07, HER2:-0.34, Triple_Negative:0.94 | |
36 | hsa-miR-429 | FZD4 | 0.45 | 0.43718 | -0.76 | 0.18617 | mirMAP | -0.42 | 0 | NA | -0.25 | type:-3.21, stage:-0.07, histology:-0.02, PAM50:0, ER:0.02, PR:-0.17, HER2:0.06, Triple_Negative:-0.8 | |
37 | hsa-miR-26a-5p | VANGL1 | -0.05 | 0.95817 | 0.09 | 0.85194 | mirMAP | -0.38 | 0 | NA | -0.25 | type:1.19, stage:0.01, histology:0.01, PAM50:0.04, ER:-0.26, PR:0.09, HER2:0.17, Triple_Negative:0.03 | |
38 | hsa-miR-182-5p | DAAM2 | -0.35 | 0.79413 | -0.04 | 0.92488 | mirMAP | -0.43 | 0 | NA | -0.24 | type:-1.67, stage:0.02, histology:0.1, PAM50:-0.15, ER:0.32, PR:-0.11, HER2:-0.17, Triple_Negative:-0.26 | |
39 | hsa-miR-374a-5p | CCND1 | 0.47 | 0.30955 | -1.64 | 0.03536 | MirTarget | -0.56 | 0 | 27191497 | microRNA 374a suppresses colon cancer progression by directly reducing CCND1 to inactivate the PI3K/AKT pathway; Furthermore luciferase reporter assays confirmed that miR-374a could directly reduce CCND1; We examined miR-374a levels by in situ hybridization and its correlation with CCND1 expression in CRC tumor tissues; High miR-374a expression with low level of CCND1 was protective factor in CRC; Together these findings indicate that miR-374a inactivates the PI3K/AKT axis by inhibiting CCND1 suppressing of colon cancer progression | -0.23 | type:2.74, stage:0.02, histology:0.03, PAM50:0.27, ER:1.01, PR:-0.19, HER2:0.22, Triple_Negative:-0.07 |
40 | hsa-miR-664a-3p | WNT10A | -0.25 | 0.59988 | 2.09 | 0 | mirMAP | -0.42 | 0 | NA | -0.23 | type:-1.33, stage:0.07, histology:-0.16, PAM50:-0.41, ER:-0.25, PR:0.09, HER2:-0.37, Triple_Negative:0.87 | |
41 | hsa-miR-3127-5p | FZD4 | 0.15 | 0.56685 | -0.76 | 0.18617 | MirTarget | -0.35 | 0 | NA | -0.22 | type:-4.2, stage:-0.04, histology:-0.03, PAM50:0.04, ER:-0.24, PR:-0.14, HER2:0.15, Triple_Negative:-0.98 | |
42 | hsa-miR-30d-5p | WNT5A | 0.17 | 0.88286 | -0.49 | 0.23864 | mirMAP | -0.4 | 0 | NA | -0.22 | type:1.88, stage:-0.21, histology:-0.12, PAM50:-0.05, ER:0.1, PR:0.76, HER2:0.37, Triple_Negative:0.19 | |
43 | hsa-miR-17-5p | FZD4 | 1.81 | 0.01774 | -0.76 | 0.18617 | TargetScan | -0.38 | 0 | NA | -0.21 | type:-4.29, stage:-0.04, histology:-0.03, PAM50:-0.03, ER:-0.33, PR:-0.09, HER2:0.09, Triple_Negative:-0.83 | |
44 | hsa-miR-21-5p | FZD4 | -0.14 | 0.92885 | -0.76 | 0.18617 | mirMAP | -0.62 | 0 | NA | -0.21 | type:-3.77, stage:-0.05, histology:-0.03, PAM50:-0.01, ER:-0.16, PR:-0.04, HER2:0.2, Triple_Negative:-1 | |
45 | hsa-let-7i-5p | NLK | 0.49 | 0.5398 | -0.5 | 0.25036 | miRNATAP | -0.41 | 0 | NA | -0.21 | type:1.13, stage:0.01, histology:0, PAM50:0.13, ER:-0.06, PR:0.02, HER2:0.3, Triple_Negative:-0.11 | |
46 | hsa-miR-183-5p | PRKCA | 0.2 | 0.86335 | 1.09 | 0.00099 | miRNATAP | -0.38 | 0 | NA | -0.21 | type:-2.18, stage:-0.04, histology:-0.06, PAM50:-0.29, ER:-0.09, PR:-0.25, HER2:-0.12, Triple_Negative:0.17 | |
47 | hsa-miR-106b-5p | FZD4 | 1.05 | 0.13909 | -0.76 | 0.18617 | miRNATAP | -0.58 | 0 | NA | -0.2 | type:-4.18, stage:-0.05, histology:-0.03, PAM50:-0.01, ER:-0.26, PR:-0.08, HER2:0.09, Triple_Negative:-0.9 | |
48 | hsa-miR-590-3p | PRICKLE2 | 1.01 | 0 | -1.2 | 0.01176 | MirTarget; PITA; miRanda; mirMAP; miRNATAP | -0.43 | 0 | NA | -0.2 | type:-1.18, stage:-0.07, histology:-0.02, PAM50:0.05, ER:0.14, PR:0.17, HER2:0.23, Triple_Negative:-0.63 | |
49 | hsa-miR-200c-3p | PRKCA | 0.37 | 0.75644 | 1.09 | 0.00099 | miRNATAP | -0.38 | 0 | NA | -0.2 | type:-2.33, stage:-0.03, histology:-0.06, PAM50:-0.28, ER:-0.07, PR:-0.24, HER2:-0.17, Triple_Negative:0.23 | |
50 | hsa-miR-625-5p | SFRP1 | -0.13 | 0.46001 | 3.81 | 0 | MirTarget | -0.63 | 0 | NA | -0.2 | type:-5.05, stage:-0.1, histology:-0.11, PAM50:-1.1, ER:0.61, PR:-0.14, HER2:-0.94, Triple_Negative:1.75 | |
51 | hsa-miR-148b-3p | TCF7L2 | 0.14 | 0.82572 | 0.81 | 0.09031 | miRNAWalker2 validate | -0.36 | 0 | NA | -0.2 | type:-1.45, stage:-0.06, histology:-0.05, PAM50:-0.28, ER:0.04, PR:-0.03, HER2:-0.02, Triple_Negative:0.23 | |
52 | hsa-miR-186-5p | CCND1 | 1.04 | 0.14871 | -1.64 | 0.03536 | mirMAP | -0.49 | 0 | NA | -0.19 | type:2.53, stage:0.02, histology:0.04, PAM50:0.26, ER:0.88, PR:-0.16, HER2:0.16, Triple_Negative:-0.1 | |
53 | hsa-miR-374b-5p | CCND1 | 0.48 | 0.36577 | -1.64 | 0.03536 | miRNAWalker2 validate; MirTarget | -0.53 | 0 | NA | -0.19 | type:2.66, stage:0.02, histology:0.03, PAM50:0.27, ER:1, PR:-0.17, HER2:0.2, Triple_Negative:-0.1 | |
54 | hsa-let-7a-3p | FZD4 | 0.31 | 0.49951 | -0.76 | 0.18617 | mirMAP | -0.41 | 0 | NA | -0.19 | type:-3.99, stage:-0.05, histology:-0.02, PAM50:0, ER:-0.14, PR:-0.05, HER2:0.1, Triple_Negative:-0.89 | |
55 | hsa-miR-18a-5p | PRICKLE2 | 2.3 | 0 | -1.2 | 0.01176 | MirTarget | -0.39 | 0 | NA | -0.19 | type:-1.1, stage:-0.06, histology:-0.02, PAM50:0.04, ER:0.13, PR:0.11, HER2:0.24, Triple_Negative:-0.46 | |
56 | hsa-miR-19a-3p | PRICKLE2 | 1.47 | 0.00036 | -1.2 | 0.01176 | MirTarget; miRNATAP | -0.4 | 0 | NA | -0.19 | type:-1.25, stage:-0.06, histology:-0.02, PAM50:0.06, ER:0.15, PR:0.13, HER2:0.22, Triple_Negative:-0.57 | |
57 | hsa-miR-19b-3p | PRICKLE2 | 1.16 | 0.06285 | -1.2 | 0.01176 | MirTarget; miRNATAP | -0.4 | 0 | NA | -0.19 | type:-1.31, stage:-0.07, histology:-0.01, PAM50:0.06, ER:0.17, PR:0.18, HER2:0.18, Triple_Negative:-0.57 | |
58 | hsa-miR-590-5p | PRICKLE2 | 1.4 | 0 | -1.2 | 0.01176 | MirTarget; PITA; miRanda | -0.4 | 0 | NA | -0.19 | type:-1.55, stage:-0.06, histology:-0.02, PAM50:0.05, ER:0.05, PR:0.15, HER2:0.19, Triple_Negative:-0.68 | |
59 | hsa-miR-15a-5p | CCND2 | 0.34 | 0.60504 | -0.07 | 0.88928 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.38 | 0 | NA | -0.18 | type:-1.47, stage:-0.04, histology:-0.09, PAM50:-0.06, ER:-0.01, PR:0.18, HER2:0, Triple_Negative:-0.01 | |
60 | hsa-miR-192-5p | FZD4 | 0.47 | 0.53116 | -0.76 | 0.18617 | miRNAWalker2 validate; mirMAP | -0.42 | 0 | NA | -0.18 | type:-4.21, stage:-0.05, histology:-0.02, PAM50:0, ER:-0.25, PR:-0.09, HER2:0.12, Triple_Negative:-1 | |
61 | hsa-miR-93-5p | PLCB1 | 0.94 | 0.3985 | -0.07 | 0.85874 | miRNATAP | -0.38 | 0 | NA | -0.18 | type:-3.61, stage:0.12, histology:-0.04, PAM50:-0.17, ER:-0.46, PR:-0.04, HER2:0.18, Triple_Negative:-0.68 | |
62 | hsa-miR-330-5p | SOX17 | 0.56 | 0.19479 | -0.56 | 0.03082 | miRanda | -0.46 | 0 | NA | -0.18 | type:-2.24, stage:-0.06, histology:0.02, PAM50:-0.01, ER:0.09, PR:0.08, HER2:0.01, Triple_Negative:-0.26 | |
63 | hsa-miR-429 | MAPK10 | 0.45 | 0.43718 | -0.14 | 0.64996 | miRNATAP | -0.37 | 0 | NA | -0.17 | type:-0.26, stage:-0.3, histology:-0.11, PAM50:-0.01, ER:0.31, PR:0, HER2:0.38, Triple_Negative:0.29 | |
64 | hsa-miR-185-5p | NFATC2 | 0.41 | 0.43546 | -0.4 | 0.13655 | MirTarget | -0.48 | 0 | NA | -0.17 | type:-2.44, stage:-0.02, histology:-0.07, PAM50:-0.09, ER:0.25, PR:0.11, HER2:-0.35, Triple_Negative:-0.34 | |
65 | hsa-miR-107 | PLCB1 | 0.35 | 0.52382 | -0.07 | 0.85874 | PITA; miRanda; miRNATAP | -0.44 | 0 | NA | -0.16 | type:-3.37, stage:0.1, histology:-0.04, PAM50:-0.14, ER:-0.38, PR:-0.02, HER2:0.2, Triple_Negative:-0.64 | |
66 | hsa-miR-98-5p | FZD4 | 0.61 | 0.24397 | -0.76 | 0.18617 | MirTarget | -0.53 | 0 | NA | -0.15 | type:-4.23, stage:-0.03, histology:-0.03, PAM50:-0.02, ER:-0.19, PR:-0.03, HER2:0.11, Triple_Negative:-0.93 | |
67 | hsa-miR-148b-3p | PRICKLE2 | 0.14 | 0.82572 | -1.2 | 0.01176 | MirTarget; miRNATAP | -0.37 | 0 | NA | -0.15 | type:-1.19, stage:-0.08, histology:-0.01, PAM50:0.09, ER:0.2, PR:0.17, HER2:0.22, Triple_Negative:-0.69 | |
68 | hsa-miR-15b-3p | PRICKLE2 | 1.34 | 0.00123 | -1.2 | 0.01176 | mirMAP | -0.35 | 0 | NA | -0.15 | type:-1.02, stage:-0.07, histology:-0.02, PAM50:0.08, ER:0.18, PR:0.16, HER2:0.23, Triple_Negative:-0.55 | |
69 | hsa-miR-130b-3p | FZD4 | 1.17 | 7.0E-5 | -0.76 | 0.18617 | mirMAP | -0.41 | 0 | NA | -0.14 | type:-4.01, stage:-0.05, histology:-0.03, PAM50:0, ER:-0.26, PR:-0.06, HER2:0.15, Triple_Negative:-0.89 | |
70 | hsa-miR-590-3p | FZD4 | 1.01 | 0 | -0.76 | 0.18617 | miRanda; mirMAP; miRNATAP | -0.41 | 0 | NA | -0.14 | type:-4.19, stage:-0.05, histology:-0.03, PAM50:-0.02, ER:-0.25, PR:-0.05, HER2:0.12, Triple_Negative:-0.95 | |
71 | hsa-miR-106b-5p | PLCB1 | 1.05 | 0.13909 | -0.07 | 0.85874 | miRNATAP | -0.35 | 0 | NA | -0.14 | type:-3.44, stage:0.1, histology:-0.04, PAM50:-0.16, ER:-0.42, PR:-0.04, HER2:0.18, Triple_Negative:-0.65 | |
72 | hsa-miR-361-5p | MAPK8 | 0.3 | 0.67981 | 0.14 | 0.68637 | PITA; miRanda; mirMAP | -0.36 | 0 | NA | -0.13 | type:-0.52, stage:-0.02, histology:-0.01, PAM50:0, ER:0.04, PR:-0.19, HER2:-0.17, Triple_Negative:-0.01 | |
73 | hsa-miR-429 | SFRP1 | 0.45 | 0.43718 | 3.81 | 0 | miRNATAP | -0.48 | 0 | NA | -0.13 | type:-5.59, stage:-0.14, histology:-0.12, PAM50:-1.12, ER:0.57, PR:-0.24, HER2:-1.09, Triple_Negative:1.63 | |
74 | hsa-let-7d-5p | FZD4 | 0.74 | 0.278 | -0.76 | 0.18617 | MirTarget; miRNATAP | -0.38 | 0 | NA | -0.11 | type:-4.26, stage:-0.05, histology:-0.03, PAM50:-0.02, ER:-0.2, PR:-0.03, HER2:0.1, Triple_Negative:-0.94 | |
75 | hsa-miR-32-5p | FZD4 | 0.53 | 0.1955 | -0.76 | 0.18617 | mirMAP | -0.39 | 0 | NA | -0.1 | type:-4.17, stage:-0.05, histology:-0.02, PAM50:0, ER:-0.22, PR:-0.04, HER2:0.11, Triple_Negative:-0.96 | |
76 | hsa-miR-590-5p | SOX17 | 1.4 | 0 | -0.56 | 0.03082 | miRanda | -0.39 | 0 | NA | -0.1 | type:-2.84, stage:-0.05, histology:0.02, PAM50:-0.03, ER:-0.02, PR:0.06, HER2:-0.04, Triple_Negative:-0.39 | |
77 | hsa-miR-429 | WIF1 | 0.45 | 0.43718 | 2.05 | 3.0E-5 | miRanda | -0.58 | 0 | NA | -0.1 | type:-4.24, stage:-0.35, histology:-0.13, PAM50:-0.56, ER:0.23, PR:0.15, HER2:-0.23, Triple_Negative:1.36 | |
78 | hsa-miR-361-5p | PPP2R5E | 0.3 | 0.67981 | -0.11 | 0.80826 | miRanda | -0.36 | 0 | NA | -0.09 | type:0.13, stage:0.04, histology:0.01, PAM50:0, ER:-0.14, PR:0, HER2:0.19, Triple_Negative:-0.18 | |
79 | hsa-miR-589-5p | PRICKLE2 | 0.23 | 0.66837 | -1.2 | 0.01176 | MirTarget; miRNATAP | -0.41 | 0 | NA | -0.09 | type:-1.33, stage:-0.07, histology:-0.01, PAM50:0.07, ER:0.19, PR:0.21, HER2:0.25, Triple_Negative:-0.69 | |
80 | hsa-miR-340-5p | ROCK2 | 0.36 | 0.35065 | 0.38 | 0.43385 | mirMAP | -0.4 | 0 | NA | -0.09 | type:-2.16, stage:0, histology:0, PAM50:-0.09, ER:-0.14, PR:-0.31, HER2:-0.06, Triple_Negative:-0.23 | |
81 | hsa-miR-590-3p | SOX17 | 1.01 | 0 | -0.56 | 0.03082 | miRanda; miRNATAP | -0.44 | 0 | NA | -0.09 | type:-2.62, stage:-0.05, histology:0.02, PAM50:-0.02, ER:0.05, PR:0.07, HER2:-0.02, Triple_Negative:-0.37 | |
82 | hsa-let-7i-5p | CCND1 | 0.49 | 0.5398 | -1.64 | 0.03536 | miRNATAP | -0.76 | 0 | NA | -0.08 | type:2.76, stage:0.02, histology:0.04, PAM50:0.27, ER:1, PR:-0.14, HER2:0.19, Triple_Negative:-0.12 | |
83 | hsa-miR-92a-3p | CCND1 | 1.23 | 0.30313 | -1.64 | 0.03536 | miRNAWalker2 validate | -0.36 | 0 | NA | -0.08 | type:2.79, stage:0.02, histology:0.05, PAM50:0.27, ER:0.98, PR:-0.15, HER2:0.18, Triple_Negative:-0.08 | |
84 | hsa-miR-146b-5p | CXXC4 | 0.88 | 0.28494 | -1.31 | 0 | MirTarget; miRNATAP | -0.4 | 0 | NA | -0.08 | type:-0.44, stage:-0.15, histology:-0.06, PAM50:0.36, ER:0.52, PR:-0.66, HER2:0.18, Triple_Negative:-0.65 | |
85 | hsa-miR-107 | FZD4 | 0.35 | 0.52382 | -0.76 | 0.18617 | miRNATAP | -0.46 | 0 | NA | -0.06 | type:-4.3, stage:-0.05, histology:-0.02, PAM50:-0.01, ER:-0.2, PR:-0.02, HER2:0.11, Triple_Negative:-0.97 | |
86 | hsa-miR-340-5p | NFATC2 | 0.36 | 0.35065 | -0.4 | 0.13655 | miRNATAP | -0.38 | 0 | NA | -0.06 | type:-1.88, stage:-0.03, histology:-0.06, PAM50:-0.07, ER:0.44, PR:0.06, HER2:-0.32, Triple_Negative:-0.21 | |
87 | hsa-miR-590-3p | AXIN2 | 1.01 | 0 | -1.13 | 0.00118 | MirTarget; PITA; miRanda; miRNATAP | -0.36 | 0 | NA | -0.04 | type:1.11, stage:-0.07, histology:0.02, PAM50:0.27, ER:0.52, PR:0.26, HER2:-0.03, Triple_Negative:0.15 | |
88 | hsa-miR-342-3p | WIF1 | -0.72 | 0.32809 | 2.05 | 3.0E-5 | miRanda | -0.9 | 0 | NA | -0.04 | type:-4.35, stage:-0.35, histology:-0.13, PAM50:-0.51, ER:0.11, PR:0.19, HER2:-0.19, Triple_Negative:1.33 | |
89 | hsa-miR-29a-3p | CCND1 | 0.46 | 0.68374 | -1.64 | 0.03536 | mirMAP | -0.36 | 0 | NA | -0.03 | type:2.74, stage:0.02, histology:0.04, PAM50:0.27, ER:0.99, PR:-0.13, HER2:0.18, Triple_Negative:-0.13 | |
90 | hsa-miR-532-5p | NFATC4 | 0.84 | 0.32413 | -1.31 | 0.01393 | mirMAP | -0.35 | 0 | NA | 0 | type:0.52, stage:-0.06, histology:-0.02, PAM50:0.29, ER:0.71, PR:-0.23, HER2:-0.13, Triple_Negative:-0.32 | |
91 | hsa-miR-15a-5p | FZD4 | 0.34 | 0.60504 | -0.76 | 0.18617 | MirTarget | -0.4 | 0 | NA | 0.03 | type:-4.41, stage:-0.04, histology:-0.02, PAM50:-0.01, ER:-0.2, PR:-0.01, HER2:0.11, Triple_Negative:-1.01 | |
92 | hsa-miR-186-5p | CAMK2B | 1.04 | 0.14871 | -1.56 | 0 | miRNAWalker2 validate; miRNATAP | -0.42 | 0 | NA | 0.09 | type:3.24, stage:0.05, histology:0.07, PAM50:0.5, ER:0.75, PR:0.47, HER2:-0.15, Triple_Negative:0.46 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | WNT SIGNALING PATHWAY | 18 | 351 | 1.153e-24 | 5.365e-21 |
2 | NON CANONICAL WNT SIGNALING PATHWAY | 10 | 140 | 5.437e-15 | 1.265e-11 |
3 | CANONICAL WNT SIGNALING PATHWAY | 9 | 95 | 1.1e-14 | 1.706e-11 |
4 | NEGATIVE REGULATION OF WNT SIGNALING PATHWAY | 10 | 197 | 1.73e-13 | 2.013e-10 |
5 | REGULATION OF WNT SIGNALING PATHWAY | 11 | 310 | 4.37e-13 | 4.066e-10 |
6 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 15 | 1021 | 2.841e-12 | 2.203e-09 |
7 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 17 | 1672 | 1.837e-11 | 1.221e-08 |
8 | WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY | 6 | 39 | 2.108e-11 | 1.226e-08 |
9 | REGULATION OF CELL DIFFERENTIATION | 16 | 1492 | 4.535e-11 | 2.345e-08 |
10 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 12 | 823 | 9.505e-10 | 4.423e-07 |
11 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 13 | 1142 | 3.087e-09 | 1.306e-06 |
12 | PATTERN SPECIFICATION PROCESS | 9 | 418 | 6.772e-09 | 2.626e-06 |
13 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 15 | 1791 | 7.639e-09 | 2.734e-06 |
14 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 15 | 1848 | 1.172e-08 | 3.896e-06 |
15 | DORSAL VENTRAL AXIS SPECIFICATION | 4 | 20 | 1.959e-08 | 6.078e-06 |
16 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 13 | 1381 | 3.027e-08 | 8.802e-06 |
17 | CELL FATE COMMITMENT | 7 | 227 | 3.606e-08 | 9.871e-06 |
18 | CELLULAR RESPONSE TO RETINOIC ACID | 5 | 65 | 4.148e-08 | 1.072e-05 |
19 | POSITIVE REGULATION OF GENE EXPRESSION | 14 | 1733 | 4.905e-08 | 1.201e-05 |
20 | REGULATION OF ORGAN MORPHOGENESIS | 7 | 242 | 5.592e-08 | 1.301e-05 |
21 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 13 | 1492 | 7.565e-08 | 1.676e-05 |
22 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 13 | 1518 | 9.273e-08 | 1.961e-05 |
23 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 10 | 788 | 1.25e-07 | 2.422e-05 |
24 | CIRCULATORY SYSTEM DEVELOPMENT | 10 | 788 | 1.25e-07 | 2.422e-05 |
25 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 10 | 799 | 1.422e-07 | 2.646e-05 |
26 | CELLULAR RESPONSE TO ACID CHEMICAL | 6 | 175 | 2.054e-07 | 3.677e-05 |
27 | AXIS SPECIFICATION | 5 | 90 | 2.15e-07 | 3.706e-05 |
28 | CELLULAR RESPONSE TO LIPID | 8 | 457 | 2.631e-07 | 4.372e-05 |
29 | REGIONALIZATION | 7 | 311 | 3.078e-07 | 4.938e-05 |
30 | VASCULATURE DEVELOPMENT | 8 | 469 | 3.204e-07 | 4.969e-05 |
31 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 12 | 1395 | 3.358e-07 | 5.041e-05 |
32 | RESPONSE TO LIPID | 10 | 888 | 3.781e-07 | 5.332e-05 |
33 | REGULATION OF PROTEIN MODIFICATION PROCESS | 13 | 1710 | 3.728e-07 | 5.332e-05 |
34 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 11 | 1152 | 4.37e-07 | 5.98e-05 |
35 | POSITIVE REGULATION OF CELL CYCLE | 7 | 332 | 4.781e-07 | 6.356e-05 |
36 | REGULATION OF CELLULAR RESPONSE TO STRESS | 9 | 691 | 4.967e-07 | 6.419e-05 |
37 | RESPONSE TO RETINOIC ACID | 5 | 107 | 5.11e-07 | 6.426e-05 |
38 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 7 | 337 | 5.286e-07 | 6.473e-05 |
39 | REGULATION OF ESTABLISHMENT OF PLANAR POLARITY | 5 | 110 | 5.865e-07 | 6.997e-05 |
40 | EPITHELIUM DEVELOPMENT | 10 | 945 | 6.696e-07 | 7.6e-05 |
41 | PROTEIN PHOSPHORYLATION | 10 | 944 | 6.632e-07 | 7.6e-05 |
42 | REGULATION OF CELL CYCLE | 10 | 949 | 6.96e-07 | 7.711e-05 |
43 | TISSUE MORPHOGENESIS | 8 | 533 | 8.425e-07 | 9.117e-05 |
44 | POSITIVE REGULATION OF CELL COMMUNICATION | 12 | 1532 | 9.196e-07 | 9.508e-05 |
45 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 7 | 365 | 9.027e-07 | 9.508e-05 |
46 | MAMMARY GLAND EPITHELIUM DEVELOPMENT | 4 | 53 | 1.144e-06 | 0.0001157 |
47 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 13 | 1929 | 1.489e-06 | 0.0001469 |
48 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 10 | 1036 | 1.547e-06 | 0.0001469 |
49 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 10 | 1036 | 1.547e-06 | 0.0001469 |
50 | MORPHOGENESIS OF AN EPITHELIUM | 7 | 400 | 1.662e-06 | 0.0001516 |
51 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 12 | 1618 | 1.645e-06 | 0.0001516 |
52 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 11 | 1360 | 2.258e-06 | 0.0002021 |
53 | PEPTIDYL SERINE MODIFICATION | 5 | 148 | 2.545e-06 | 0.0002235 |
54 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 10 | 1135 | 3.523e-06 | 0.0003035 |
55 | REGULATION OF JNK CASCADE | 5 | 159 | 3.618e-06 | 0.0003061 |
56 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 6 | 289 | 3.833e-06 | 0.0003185 |
57 | NEGATIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 5 | 162 | 3.965e-06 | 0.0003237 |
58 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 7 | 470 | 4.823e-06 | 0.000387 |
59 | NEGATIVE REGULATION OF CELL COMMUNICATION | 10 | 1192 | 5.457e-06 | 0.0004304 |
60 | REGULATION OF JUN KINASE ACTIVITY | 4 | 81 | 6.314e-06 | 0.0004897 |
61 | RESPONSE TO ACID CHEMICAL | 6 | 319 | 6.754e-06 | 0.0005152 |
62 | RESPONSE TO KETONE | 5 | 182 | 6.998e-06 | 0.000525 |
63 | PHOSPHORYLATION | 10 | 1228 | 7.109e-06 | 0.000525 |
64 | STEM CELL DIFFERENTIATION | 5 | 190 | 8.625e-06 | 0.0006271 |
65 | INTRACELLULAR SIGNAL TRANSDUCTION | 11 | 1572 | 9.186e-06 | 0.0006576 |
66 | ANTERIOR POSTERIOR PATTERN SPECIFICATION | 5 | 194 | 9.543e-06 | 0.0006728 |
67 | DORSAL VENTRAL PATTERN FORMATION | 4 | 91 | 1.004e-05 | 0.0006972 |
68 | REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 5 | 197 | 1.028e-05 | 0.0007034 |
69 | REGULATION OF CELL MORPHOGENESIS | 7 | 552 | 1.377e-05 | 0.0009283 |
70 | REGULATION OF HYDROLASE ACTIVITY | 10 | 1327 | 1.408e-05 | 0.000936 |
71 | BLOOD VESSEL MORPHOGENESIS | 6 | 364 | 1.431e-05 | 0.000938 |
72 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 8 | 801 | 1.707e-05 | 0.001103 |
73 | GLAND DEVELOPMENT | 6 | 395 | 2.271e-05 | 0.001447 |
74 | REGULATION OF CELL DEVELOPMENT | 8 | 836 | 2.324e-05 | 0.001461 |
75 | REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 5 | 236 | 2.456e-05 | 0.001502 |
76 | POSITIVE REGULATION OF CELL DEATH | 7 | 605 | 2.485e-05 | 0.001502 |
77 | REGULATION OF EMBRYONIC DEVELOPMENT | 4 | 114 | 2.447e-05 | 0.001502 |
78 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 6 | 404 | 2.577e-05 | 0.001527 |
79 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 7 | 609 | 2.593e-05 | 0.001527 |
80 | REPRODUCTIVE SYSTEM DEVELOPMENT | 6 | 408 | 2.724e-05 | 0.001546 |
81 | NEGATIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 4 | 117 | 2.71e-05 | 0.001546 |
82 | MAMMARY GLAND DEVELOPMENT | 4 | 117 | 2.71e-05 | 0.001546 |
83 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 11 | 1805 | 3.396e-05 | 0.001881 |
84 | REGULATION OF RESPONSE TO STRESS | 10 | 1468 | 3.388e-05 | 0.001881 |
85 | EMBRYO DEVELOPMENT | 8 | 894 | 3.757e-05 | 0.002057 |
86 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 8 | 905 | 4.099e-05 | 0.002218 |
87 | REGULATION OF MAPK CASCADE | 7 | 660 | 4.332e-05 | 0.002317 |
88 | PEPTIDYL THREONINE MODIFICATION | 3 | 46 | 4.426e-05 | 0.00234 |
89 | TISSUE DEVELOPMENT | 10 | 1518 | 4.517e-05 | 0.002362 |
90 | POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 4 | 135 | 4.748e-05 | 0.002455 |
91 | REGULATION OF GTPASE ACTIVITY | 7 | 673 | 4.903e-05 | 0.002507 |
92 | DIGESTIVE TRACT MORPHOGENESIS | 3 | 48 | 5.033e-05 | 0.002545 |
93 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 8 | 957 | 6.092e-05 | 0.002991 |
94 | POSITIVE REGULATION OF MAPK CASCADE | 6 | 470 | 5.998e-05 | 0.002991 |
95 | RESPONSE TO TRANSFORMING GROWTH FACTOR BETA | 4 | 144 | 6.106e-05 | 0.002991 |
96 | POSITIVE REGULATION OF KINASE ACTIVITY | 6 | 482 | 6.896e-05 | 0.003342 |
97 | RESPONSE TO CYTOKINE | 7 | 714 | 7.125e-05 | 0.003418 |
98 | RHYTHMIC PROCESS | 5 | 298 | 7.455e-05 | 0.003524 |
99 | UROGENITAL SYSTEM DEVELOPMENT | 5 | 299 | 7.574e-05 | 0.003524 |
100 | POSITIVE REGULATION OF WNT SIGNALING PATHWAY | 4 | 152 | 7.535e-05 | 0.003524 |
101 | POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 4 | 154 | 7.927e-05 | 0.003616 |
102 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 11 | 1977 | 7.884e-05 | 0.003616 |
103 | GASTRULATION | 4 | 155 | 8.128e-05 | 0.003637 |
104 | REPRODUCTION | 9 | 1297 | 8.13e-05 | 0.003637 |
105 | VASCULOGENESIS | 3 | 59 | 9.355e-05 | 0.004146 |
106 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 4 | 162 | 9.645e-05 | 0.004234 |
107 | REGULATION OF MAP KINASE ACTIVITY | 5 | 319 | 0.0001027 | 0.004468 |
108 | SOMITOGENESIS | 3 | 62 | 0.0001085 | 0.00465 |
109 | TUBE MORPHOGENESIS | 5 | 323 | 0.0001089 | 0.00465 |
110 | REGULATION OF PROTEIN BINDING | 4 | 168 | 0.000111 | 0.004696 |
111 | POSITIVE REGULATION OF JUN KINASE ACTIVITY | 3 | 63 | 0.0001138 | 0.004771 |
112 | NEGATIVE REGULATION OF CELL GROWTH | 4 | 170 | 0.0001162 | 0.004785 |
113 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 7 | 771 | 0.0001153 | 0.004785 |
114 | POSITIVE REGULATION OF NON CANONICAL WNT SIGNALING PATHWAY | 2 | 11 | 0.0001186 | 0.004842 |
115 | REGULATION OF KINASE ACTIVITY | 7 | 776 | 0.00012 | 0.004857 |
116 | POSITIVE REGULATION OF ENDOTHELIAL CELL MIGRATION | 3 | 67 | 0.0001367 | 0.005438 |
117 | REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 3 | 67 | 0.0001367 | 0.005438 |
118 | REGULATION OF OSSIFICATION | 4 | 178 | 0.0001387 | 0.00547 |
119 | HEART FORMATION | 2 | 12 | 0.0001422 | 0.005515 |
120 | MAMMARY GLAND EPITHELIAL CELL PROLIFERATION | 2 | 12 | 0.0001422 | 0.005515 |
121 | TUBE DEVELOPMENT | 6 | 552 | 0.0001452 | 0.005585 |
122 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 6 | 554 | 0.0001481 | 0.005603 |
123 | NEUROGENESIS | 9 | 1402 | 0.0001479 | 0.005603 |
124 | REGULATION OF CELL CYCLE PROCESS | 6 | 558 | 0.000154 | 0.00578 |
125 | PROTEIN AUTOPHOSPHORYLATION | 4 | 192 | 0.0001855 | 0.006852 |
126 | RESPONSE TO ALCOHOL | 5 | 362 | 0.0001855 | 0.006852 |
127 | REGULATION OF ESTABLISHMENT OF PLANAR POLARITY INVOLVED IN NEURAL TUBE CLOSURE | 2 | 14 | 0.0001957 | 0.006952 |
128 | POSITIVE REGULATION OF MEIOTIC CELL CYCLE | 2 | 14 | 0.0001957 | 0.006952 |
129 | CELL MIGRATION INVOLVED IN GASTRULATION | 2 | 14 | 0.0001957 | 0.006952 |
130 | CONVERGENT EXTENSION | 2 | 14 | 0.0001957 | 0.006952 |
131 | REGULATION OF SYNAPSE MATURATION | 2 | 14 | 0.0001957 | 0.006952 |
132 | ORGAN MORPHOGENESIS | 7 | 841 | 0.0001976 | 0.006964 |
133 | REGULATION OF CELL DEATH | 9 | 1472 | 0.0002142 | 0.007457 |
134 | SOMITE DEVELOPMENT | 3 | 78 | 0.0002148 | 0.007457 |
135 | DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 6 | 602 | 0.0002325 | 0.008012 |
136 | REGULATION OF CELL PROLIFERATION | 9 | 1496 | 0.000242 | 0.00828 |
137 | JNK CASCADE | 3 | 82 | 0.000249 | 0.008377 |
138 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 4 | 207 | 0.0002474 | 0.008377 |
139 | NEURON DIFFERENTIATION | 7 | 874 | 0.0002502 | 0.008377 |
140 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 7 | 876 | 0.0002538 | 0.008434 |
141 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 6 | 616 | 0.0002631 | 0.008683 |
142 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 9 | 1517 | 0.0002688 | 0.008745 |
143 | NEGATIVE REGULATION OF DEVELOPMENTAL GROWTH | 3 | 84 | 0.0002673 | 0.008745 |
144 | DEVELOPMENT OF PRIMARY SEXUAL CHARACTERISTICS | 4 | 216 | 0.0002909 | 0.009399 |
145 | REGULATION OF CELL ADHESION | 6 | 629 | 0.0002944 | 0.009447 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | FRIZZLED BINDING | 5 | 36 | 1.952e-09 | 1.813e-06 |
2 | WNT PROTEIN BINDING | 4 | 31 | 1.258e-07 | 5.843e-05 |
3 | PROTEIN KINASE ACTIVITY | 9 | 640 | 2.606e-07 | 6.053e-05 |
4 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 8 | 445 | 2.148e-07 | 6.053e-05 |
5 | MAP KINASE ACTIVITY | 3 | 14 | 1.096e-06 | 0.0002037 |
6 | KINASE ACTIVITY | 9 | 842 | 2.564e-06 | 0.000397 |
7 | ENZYME BINDING | 12 | 1737 | 3.476e-06 | 0.0004613 |
8 | WNT ACTIVATED RECEPTOR ACTIVITY | 3 | 22 | 4.601e-06 | 0.0005342 |
9 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 9 | 992 | 9.748e-06 | 0.001006 |
10 | PROTEIN DOMAIN SPECIFIC BINDING | 7 | 624 | 3.03e-05 | 0.002815 |
11 | G PROTEIN COUPLED RECEPTOR BINDING | 5 | 259 | 3.831e-05 | 0.003236 |
12 | MOLECULAR FUNCTION REGULATOR | 9 | 1353 | 0.0001126 | 0.00805 |
13 | TRANSCRIPTION FACTOR BINDING | 6 | 524 | 0.0001092 | 0.00805 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | ENDOCYTIC VESICLE MEMBRANE | 6 | 152 | 8.914e-08 | 5.206e-05 |
2 | ENDOCYTIC VESICLE | 6 | 256 | 1.903e-06 | 0.0005558 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | hsa04310_Wnt_signaling_pathway | 30 | 151 | 1.014e-65 | 1.826e-63 | |
2 | hsa04916_Melanogenesis | 12 | 101 | 1.123e-20 | 1.011e-18 | |
3 | hsa04390_Hippo_signaling_pathway | 10 | 154 | 1.435e-14 | 8.613e-13 | |
4 | hsa04912_GnRH_signaling_pathway | 7 | 101 | 1.255e-10 | 5.649e-09 | |
5 | hsa04340_Hedgehog_signaling_pathway | 5 | 56 | 1.937e-08 | 6.972e-07 | |
6 | hsa04720_Long.term_potentiation | 5 | 70 | 6.047e-08 | 1.814e-06 | |
7 | hsa04971_Gastric_acid_secretion | 5 | 74 | 8.015e-08 | 2.061e-06 | |
8 | hsa04010_MAPK_signaling_pathway | 7 | 268 | 1.122e-07 | 2.525e-06 | |
9 | hsa04012_ErbB_signaling_pathway | 5 | 87 | 1.814e-07 | 3.627e-06 | |
10 | hsa04510_Focal_adhesion | 6 | 200 | 4.51e-07 | 8.118e-06 | |
11 | hsa04020_Calcium_signaling_pathway | 5 | 177 | 6.11e-06 | 9.999e-05 | |
12 | hsa04114_Oocyte_meiosis | 4 | 114 | 2.447e-05 | 0.0003628 | |
13 | hsa04270_Vascular_smooth_muscle_contraction | 4 | 116 | 2.62e-05 | 0.0003628 | |
14 | hsa04722_Neurotrophin_signaling_pathway | 4 | 127 | 3.739e-05 | 0.0004627 | |
15 | hsa04380_Osteoclast_differentiation | 4 | 128 | 3.856e-05 | 0.0004627 | |
16 | hsa04370_VEGF_signaling_pathway | 3 | 76 | 0.0001988 | 0.002237 | |
17 | hsa04664_Fc_epsilon_RI_signaling_pathway | 3 | 79 | 0.000223 | 0.002361 | |
18 | hsa04914_Progesterone.mediated_oocyte_maturation | 3 | 87 | 0.0002965 | 0.002949 | |
19 | hsa04970_Salivary_secretion | 3 | 89 | 0.000317 | 0.002949 | |
20 | hsa04540_Gap_junction | 3 | 90 | 0.0003276 | 0.002949 | |
21 | hsa04360_Axon_guidance | 3 | 130 | 0.0009582 | 0.008213 | |
22 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 3 | 136 | 0.001092 | 0.00891 | |
23 | hsa04910_Insulin_signaling_pathway | 3 | 138 | 0.001139 | 0.00891 | |
24 | hsa04151_PI3K_AKT_signaling_pathway | 4 | 351 | 0.001782 | 0.01336 | |
25 | hsa04062_Chemokine_signaling_pathway | 3 | 189 | 0.002795 | 0.02012 | |
26 | hsa04621_NOD.like_receptor_signaling_pathway | 2 | 59 | 0.003529 | 0.02443 | |
27 | hsa04920_Adipocytokine_signaling_pathway | 2 | 68 | 0.004659 | 0.0301 | |
28 | hsa04115_p53_signaling_pathway | 2 | 69 | 0.004794 | 0.0301 | |
29 | hsa04730_Long.term_depression | 2 | 70 | 0.004931 | 0.0301 | |
30 | hsa04622_RIG.I.like_receptor_signaling_pathway | 2 | 71 | 0.005069 | 0.0301 | |
31 | hsa04014_Ras_signaling_pathway | 3 | 236 | 0.005206 | 0.0301 | |
32 | hsa04520_Adherens_junction | 2 | 73 | 0.00535 | 0.0301 | |
33 | hsa04662_B_cell_receptor_signaling_pathway | 2 | 75 | 0.005639 | 0.03076 | |
34 | hsa04070_Phosphatidylinositol_signaling_system | 2 | 78 | 0.006086 | 0.03222 | |
35 | hsa04972_Pancreatic_secretion | 2 | 101 | 0.01002 | 0.05104 | |
36 | hsa04620_Toll.like_receptor_signaling_pathway | 2 | 102 | 0.01021 | 0.05104 | |
37 | hsa04660_T_cell_receptor_signaling_pathway | 2 | 108 | 0.01139 | 0.0554 | |
38 | hsa04670_Leukocyte_transendothelial_migration | 2 | 117 | 0.01326 | 0.06283 | |
39 | hsa04110_Cell_cycle | 2 | 128 | 0.01573 | 0.07258 | |
40 | hsa04740_Olfactory_transduction | 3 | 388 | 0.01996 | 0.08983 | |
41 | hsa04630_Jak.STAT_signaling_pathway | 2 | 155 | 0.02252 | 0.09888 | |
42 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 2 | 168 | 0.02616 | 0.1121 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | RP11-736K20.5 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-590-3p | 10 | FZD4 | Sponge network | -1.12 | 0 | -0.757 | 0.18617 | 0.911 |
2 | RP11-175K6.1 | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-330-5p;hsa-miR-98-5p | 10 | FZD4 | Sponge network | -0.575 | 0.00197 | -0.757 | 0.18617 | 0.797 |
3 | RP11-1101K5.1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p | 12 | FZD4 | Sponge network | -0.926 | 0.2253 | -0.757 | 0.18617 | 0.645 |
4 | TRHDE-AS1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-32-5p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-98-5p | 19 | FZD4 | Sponge network | -1.208 | 0.04058 | -0.757 | 0.18617 | 0.639 |
5 | ADIPOQ-AS1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-590-3p | 15 | FZD4 | Sponge network | -0.771 | 0.3685 | -0.757 | 0.18617 | 0.618 |
6 | ADAMTS9-AS2 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-32-5p;hsa-miR-590-3p;hsa-miR-98-5p | 16 | FZD4 | Sponge network | -0.668 | 0.037 | -0.757 | 0.18617 | 0.617 |
7 | MIR143HG | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-32-5p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-98-5p | 18 | FZD4 | Sponge network | -0.86 | 0.00094 | -0.757 | 0.18617 | 0.604 |
8 | EMX2OS | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-32-5p;hsa-miR-330-5p;hsa-miR-590-3p | 16 | FZD4 | Sponge network | -0.677 | 0.02209 | -0.757 | 0.18617 | 0.585 |
9 | AL035610.1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-590-3p | 16 | FZD4 | Sponge network | -1.553 | 0.00698 | -0.757 | 0.18617 | 0.581 |
10 | ADAMTS9-AS1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-32-5p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-98-5p | 18 | FZD4 | Sponge network | -0.962 | 0.04922 | -0.757 | 0.18617 | 0.572 |
11 | ALDH1L1-AS2 | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-590-3p | 13 | FZD4 | Sponge network | 0.289 | 0.67904 | -0.757 | 0.18617 | 0.564 |
12 | RP11-384P7.7 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-98-5p | 14 | FZD4 | Sponge network | -1.959 | 2.0E-5 | -0.757 | 0.18617 | 0.558 |
13 | MEG3 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-98-5p | 10 | FZD4 | Sponge network | -0.963 | 0 | -0.757 | 0.18617 | 0.539 |
14 | PGM5-AS1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-200b-3p;hsa-miR-200c-3p | 10 | FZD4 | Sponge network | -2.259 | 0.00169 | -0.757 | 0.18617 | 0.53 |
15 | LINC00968 | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-590-3p | 11 | FZD4 | Sponge network | 0.742 | 0.04551 | -0.757 | 0.18617 | 0.52 |
16 | AGAP11 | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-330-5p | 12 | FZD4 | Sponge network | -1.402 | 0 | -0.757 | 0.18617 | 0.513 |
17 | RP11-92A5.2 | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-590-3p | 12 | FZD4 | Sponge network | -1.261 | 0.13256 | -0.757 | 0.18617 | 0.487 |
18 | AC108142.1 | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-429;hsa-miR-590-3p;hsa-miR-98-5p | 10 | FZD4 | Sponge network | -0.622 | 0.11008 | -0.757 | 0.18617 | 0.482 |
19 | RP11-180N14.1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-21-5p;hsa-miR-98-5p | 10 | FZD4 | Sponge network | -1.548 | 0 | -0.757 | 0.18617 | 0.481 |
20 | DIO3OS | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-98-5p | 13 | FZD4 | Sponge network | -1.023 | 0.0019 | -0.757 | 0.18617 | 0.471 |
21 | AC003991.3 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-21-5p;hsa-miR-32-5p;hsa-miR-590-3p | 13 | FZD4 | Sponge network | -0.951 | 0.00515 | -0.757 | 0.18617 | 0.465 |
22 | AC004947.2 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-330-5p;hsa-miR-590-3p | 15 | FZD4 | Sponge network | -2.525 | 0 | -0.757 | 0.18617 | 0.437 |
23 | RP11-116O18.1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-590-3p;hsa-miR-98-5p | 13 | FZD4 | Sponge network | -2.5 | 0 | -0.757 | 0.18617 | 0.431 |
24 | RP11-276H19.1 | hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-590-3p;hsa-miR-98-5p | 10 | FZD4 | Sponge network | 0.128 | 0.62793 | -0.757 | 0.18617 | 0.423 |
25 | ACTA2-AS1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-330-5p;hsa-miR-590-3p | 14 | FZD4 | Sponge network | -0.715 | 0.01146 | -0.757 | 0.18617 | 0.42 |
26 | RP11-822E23.8 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-330-5p | 13 | FZD4 | Sponge network | -2.084 | 0 | -0.757 | 0.18617 | 0.42 |
27 | RP11-286B14.1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-590-3p;hsa-miR-98-5p | 12 | FZD4 | Sponge network | 0.222 | 0.70649 | -0.757 | 0.18617 | 0.375 |
28 | LINC00648 | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-590-3p | 14 | FZD4 | Sponge network | -1.323 | 0.05538 | -0.757 | 0.18617 | 0.375 |
29 | AC141928.1 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-98-5p | 11 | FZD4 | Sponge network | -3.06 | 0 | -0.757 | 0.18617 | 0.344 |
30 | RP11-507B12.2 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-330-5p;hsa-miR-98-5p | 13 | FZD4 | Sponge network | -4.402 | 0 | -0.757 | 0.18617 | 0.343 |
31 | RP11-276H19.2 | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-192-5p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-590-3p;hsa-miR-98-5p | 10 | FZD4 | Sponge network | 0.056 | 0.92103 | -0.757 | 0.18617 | 0.339 |
32 | RP11-978I15.10 | hsa-let-7a-3p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-429 | 11 | FZD4 | Sponge network | -4.189 | 0 | -0.757 | 0.18617 | 0.332 |
33 | RP11-403B2.7 | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-21-5p;hsa-miR-590-3p | 10 | FZD4 | Sponge network | -1.412 | 2.0E-5 | -0.757 | 0.18617 | 0.317 |
34 | LINC01085 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-429;hsa-miR-590-3p | 15 | FZD4 | Sponge network | -2.762 | 0 | -0.757 | 0.18617 | 0.298 |
35 | CTB-107G13.1 | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-21-5p;hsa-miR-330-5p;hsa-miR-590-3p | 11 | FZD4 | Sponge network | -4.202 | 0 | -0.757 | 0.18617 | 0.291 |
36 | CTD-3247F14.2 | hsa-let-7a-3p;hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-330-5p;hsa-miR-98-5p | 12 | FZD4 | Sponge network | -1.581 | 0.00115 | -0.757 | 0.18617 | 0.276 |
37 | RP11-398E10.1 | hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-590-3p;hsa-miR-98-5p | 10 | FZD4 | Sponge network | -1.149 | 0.16482 | -0.757 | 0.18617 | 0.272 |
38 | LDLRAD4-AS1 | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-3127-5p;hsa-miR-590-3p | 10 | FZD4 | Sponge network | -4.332 | 0 | -0.757 | 0.18617 | 0.258 |
39 | RP11-32B5.7 | hsa-let-7d-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-130b-3p;hsa-miR-15a-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-192-5p;hsa-miR-21-5p;hsa-miR-3127-5p;hsa-miR-590-3p | 11 | FZD4 | Sponge network | -2.009 | 1.0E-5 | -0.757 | 0.18617 | 0.255 |